The deal that the vaccine alliance of the Netherlands, Germany, France and Italy made with AstraZeneca, for the supply of 300 to 400 million potential vaccines, has been taken over by the European Commission (EC). That means less financial burden for the cabinet. The question is whether a smaller proportion of the vaccines will eventually go to the Netherlands.

This confirms a spokesman for the Ministry of Health in conversation with

The vaccine from the pharmaceutical company AstraZeneca has not yet entered production. The drug must first go through a few more clinical trials, during which the vaccine is tested on tens of thousands of participants for side effects and other health risks. Promising results were achieved in earlier research phases.

If the development of the vaccine proceeds successfully, 300 to 400 million vaccines may be gradually available for Europe by the end of this year. The vaccines would be distributed based on the population.

In mid-June, EC started collective surgery in the race for vaccine

The vaccine alliance invited other EU member states to join the four countries in order to create an even stronger negotiating position in the vaccine market. In the end, the European Commission announced in mid-June that it would now come up with a collective European strategy to obtain a vaccine as one united party.

Deals largely consist of support for the pharmaceutical companies, which see their costs for the research and the final production being financed. In return, the paying party receives a large dose of vaccines. In this way, the risks of pharmaceutical companies are also covered.

The EC writes in a press release that use is made of the emergency fund (ESI), but does not specify the amount that will be paid for the delivery. President Ursula von der Leyen calls the deal "an opportunity to later deliver vaccines to all Europeans and partners".